Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current TherapyDanielle Drayton2020-10-05T13:14:26+00:00September 30th, 2020|Read More
The Challenges of Pediatric to Adult Care Transitions for Sickle Cell Disease PatientsDanielle Drayton2020-07-02T15:27:45+00:00July 2nd, 2020|Read More
Three Developments That Will Irreversibly Shape the Sickle Cell Disease Therapy MarketDanielle Drayton2020-05-18T16:59:23+00:00May 18th, 2020|Read More
Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current TherapyDanielle Drayton2020-10-05T13:14:26+00:00September 30th, 2020|Read More
The Challenges of Pediatric to Adult Care Transitions for Sickle Cell Disease PatientsDanielle Drayton2020-07-02T15:27:45+00:00July 2nd, 2020|Read More
Three Developments That Will Irreversibly Shape the Sickle Cell Disease Therapy MarketDanielle Drayton2020-05-18T16:59:23+00:00May 18th, 2020|Read More
